marked.bio

Company

Allist Pharmaceuticals

10 active trials that select patients by a biomarker on marked.bio, across 3 biomarkers; 4 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

glecirasib 6furmonertinib 4sitneprotafib 2osimertinib 1tislelizumab 1gefitinib 1cetuximab 1

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

10 of 14 trials shown

  1. A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

    Recruiting Phase 3 Allist Pharmaceuticals Started 2024Primary completion 2029-03 NCT06970639

    furmonertinibcarboplatincisplatinpemetrexedosimertinib FDA EU

    Confirmed EGFR sensitizing mutations (ex19del or L858R) via tumor tissue/cytology/blood testing;

    EGFR exon 19 deletion / L858RNSCLC Patients With Brain Metastasis

  2. JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

    Recruiting Phase 3 Allist Pharmaceuticals Started 2024Primary completion 2029-09 NCT06416410

    glecirasibtislelizumabsitneprotafibpemetrexedcarboplatin

    G12C mutation confirmed by the central lab

    KRAS G12CAdvanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer

  3. To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

    Recruiting Phase 3 Allist Pharmaceuticals Started 2021Primary completion 2026-12 NCT04853342

    furmonertinib

    …bors one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations including T790M.

    EGFR exon 19 deletion / L858RNon-small Cell Lung Carcinoma

  4. Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

    Active, not recruiting Phase 3 Allist Pharmaceuticals Started 2019Primary completion 2021-09 NCT03787992

    furmonertinibgefitinib FDA EU

    …ours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).

    EGFR exon 19 deletion / L858RLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

  5. A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

    Recruiting Phase 2 Allist Pharmaceuticals Started 2023Primary completion 2026-12 NCT06008288

    glecirasib

    Patients with the KRAS p.G12C mutation confirmed through testing using prospectively validated companion diagnostic rea…

    KRAS G12CKRAS P.G12C, Pancreatic Cancer, Solid Tumor

  6. Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

    Active, not recruiting Phase 2 Allist Pharmaceuticals Started 2022Primary completion 2025-06 NCT05466149

    furmonertinib

    …as designated by the Sponsor) of blood or tumor tissue confirming the presence of an EGFR exon 20 insertion mutation

    EGFR exon 20 insertionNSCLC

  7. A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

    Recruiting Phase 1/2 Allist Pharmaceuticals Started 2022Primary completion 2027-08 NCT05276726

    glecirasib

    Pathologically documented, locally-advanced or metastatic NSCLC with KRAS p.G12C mutation identified through molecular testing.

    KRAS G12CNon-small Cell Lung Cancer

  8. Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

    Recruiting Phase 1/2 Allist Pharmaceuticals Started 2022Primary completion 2027-03 NCT05288205

    glecirasibsitneprotafib

    …or cytologically confirmed locally advanced or metastatic advanced solid tumors harboring KRAS p.G12C mutation who have failed or lack standard-of-care (SOC) or are unwilling to undergo or in…

    KRAS G12CKRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma

  9. JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

    Active, not recruiting Phase 1/2 Allist Pharmaceuticals Started 2022Primary completion 2025-04 NCT05194995

    glecirasibcetuximab

    … colorectal cancer, advanced small intestinal cancer and advanced appendiceal cancer with KRAS p.G12C mutation

    KRAS G12CAdvanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer

  10. A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China

    Active, not recruiting Phase 1/2 Allist Pharmaceuticals Started 2021Primary completion 2026-08 NCT05009329

    glecirasib

    Advanced (metastatic or unresectable) KRAS p.G12C mutant solid tumors, with failure or absence of standard treatment

    KRAS G12CNSCLC, Solid Tumor